drugset / Trial / NCT04025372

INTREPId (INTermediate Risk Erection PreservatIon Trial)

NCT04025372

RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.

Timeline

Start
2020-06-01
Primary completion
2027-10-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified Oral
Subject Darolutamide Other / unclassified Oral

Indications